International COBRRA Trial Identifies Apixaban as Superior Anticoagulant for Reducing Severe Bleeding Risk in Venous Thrombosis Patients

The COBRRA trial finds apixaban has less than half the bleeding risk of rivaroxaban for treating venous thrombosis, signaling a major shift in clinical practice.

By: AXL Media

Published: Mar 13, 2026, 5:16 AM EDT

Source: Information for this report was sourced from The Ottawa Hospital

Redefining the Standard of Care for Venous Thrombosis

Venous thrombosis, characterized by dangerous blood clots in the legs or lungs, remains a primary cause of preventable mortality in hospitalized patients worldwide. While clinical guidelines have long recommended the use of anticoagulants like apixaban and rivaroxaban for a three-month recovery period, medical professionals have lacked a direct comparison of their safety profiles. The COBRRA trial, led by Dr. Lana Castellucci of The Ottawa Hospital, has addressed this gap by conducting the first head-to-head evaluation of these two common medications. The results indicate that while both drugs are equally effective at preventing the recurrence of clots, the safety disparity between them is significant enough to alter current prescribing practices.

Quantifying the Disparity in Bleeding Complications

The international trial enrolled 2,760 participants across Canada, Australia, and Ireland to monitor the side effects of each drug over a three-month window. The data revealed that 7.1 percent of patients treated with rivaroxaban experienced clinically relevant bleeding, compared to only 3.3 percent of those administered apixaban. This represents more than double the risk of bleeding for patients on rivaroxaban. According to Dr. Castellucci, these findings provide long-awaited evidence for physicians and offer reassurance to patients who often struggle with the competing fears of recurring clots and internal hemorrhaging.

Global Relevance of Multi-National Clinical Data

Because the study was conducted as a "standard of care" trial across diverse health systems, its findings carry substantial weight for international medicine. Patients in the trial were treated according to routine clinical practices rather than in highly artificial laboratory settings, making the results applicable to real-world patient populations. Dr. Vivien Chen of the University of Sydney noted that the participation of 32 different sites ensures that the data is relevant for a wide variety of demographic groups. This broad applicability is expected to facilitate a swift transition in how clinicians in Australia, Canada, and Ireland manage thrombosis recovery.